BTK-话题@MedSci

#BTK#

73篇内容 | 1179人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1539072, encodeId=358015390e202, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=恒瑞3.5亿美元转让BTK抑制剂，全球很大HIV组织怒斥吉利德“无耻”……, objectType=article, longId=126546, objectId=6c971265463f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c971265463f, replyNumber=0, likeNumber=40, createdTime=2018-01-17, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c971265463f, moduleTitle=恒瑞3.5亿美元转让BTK抑制剂，全球很大HIV组织怒斥吉利德“无耻”……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c971265463f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539071, encodeId=1d8415390e17a, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK选择性不可逆抑制剂的发现之旅, objectType=article, longId=116552, objectId=05a4116552da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05a4116552da, replyNumber=0, likeNumber=38, createdTime=2017-10-19, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05a4116552da, moduleTitle=BTK选择性不可逆抑制剂的发现之旅, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05a4116552da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539070, encodeId=be1515390e0c7, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：具有临床活性的BTK抑制剂PCI-32765(伊布替尼)靶向干预慢性淋巴细胞白血病B细胞受体和趋化因子调控的粘附与迁移, objectType=article, longId=116551, objectId=5a2311655152, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a2311655152, replyNumber=0, likeNumber=31, createdTime=2017-10-19, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a2311655152, moduleTitle=Blood：具有临床活性的BTK抑制剂PCI-32765(伊布替尼)靶向干预慢性淋巴细胞白血病B细胞受体和趋化因子调控的粘附与迁移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a2311655152)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539069, encodeId=9d8f153906922, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=【CSCO 2017】黄慧强教授专访：浅谈套细胞淋巴瘤的治疗及BTK抑制剂的疗效, objectType=article, longId=116549, objectId=be6711654932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6711654932, replyNumber=0, likeNumber=21, createdTime=2017-10-19, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6711654932, moduleTitle=【CSCO 2017】黄慧强教授专访：浅谈套细胞淋巴瘤的治疗及BTK抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be6711654932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539068, encodeId=9b5915390681d, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, objectType=article, longId=116540, objectId=d02a116540e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02a116540e5, replyNumber=0, likeNumber=19, createdTime=2017-10-19, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02a116540e5, moduleTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02a116540e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539067, encodeId=75b3153906ee7, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=116538, objectId=1f31116538be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f31116538be, replyNumber=0, likeNumber=25, createdTime=2017-10-19, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f31116538be, moduleTitle=全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f31116538be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539066, encodeId=24df153906601, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=111399, objectId=185911139962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185911139962, replyNumber=0, likeNumber=22, createdTime=2017-09-01, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185911139962, moduleTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185911139962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539065, encodeId=66341539065aa, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Gut：BTK激酶与食管癌, objectType=article, longId=110824, objectId=01601108246f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01601108246f, replyNumber=0, likeNumber=32, createdTime=2017-08-26, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01601108246f, moduleTitle=Gut：BTK激酶与食管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01601108246f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539064, encodeId=e798153906446, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Sci Rep：中科院刘青松教授研发出治疗类风湿性关节炎的BTK抑制剂, objectType=article, longId=96360, objectId=766896360b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=766896360b1, replyNumber=0, likeNumber=35, createdTime=2017-04-20, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=766896360b1, moduleTitle=Sci Rep：中科院刘青松教授研发出治疗类风湿性关节炎的BTK抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=766896360b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539063, encodeId=72241539063b6, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=J Immunology：BTK介导Tfh分化促进自身免疫反应的发生, objectType=article, longId=69566, objectId=8119695661e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8119695661e, replyNumber=0, likeNumber=39, createdTime=2016-06-02, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8119695661e, moduleTitle=J Immunology：BTK介导Tfh分化促进自身免疫反应的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8119695661e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539062, encodeId=0c7d153906266, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：靶向BTK新药ONO/GS-4059对耐药淋巴瘤有良好的安全性和疗效, objectType=article, longId=59141, objectId=36ca5914167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ca5914167, replyNumber=0, likeNumber=39, createdTime=2015-11-21, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ca5914167, moduleTitle=Blood：靶向BTK新药ONO/GS-4059对耐药淋巴瘤有良好的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ca5914167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539061, encodeId=c3231539061d9, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Clin Cancer Res：Ibrutinib治疗能抑制BTK和VLA-4依赖粘附的慢性淋巴细胞白血病, objectType=article, longId=52412, objectId=edd55241231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd55241231, replyNumber=0, likeNumber=22, createdTime=2015-06-25, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd55241231, moduleTitle=Clin Cancer Res：Ibrutinib治疗能抑制BTK和VLA-4依赖粘附的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd55241231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539060, encodeId=6f501539060c9, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=PNAS：酶BTK在抗病毒感染中发挥关键作用, objectType=article, longId=9222, objectId=66cc922250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cc922250, replyNumber=0, likeNumber=31, createdTime=2012-08-24, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cc922250, moduleTitle=PNAS：酶BTK在抗病毒感染中发挥关键作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cc922250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539059, encodeId=ab4c1539059ba, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=JBC: NK细胞的激活需要络氨酸激酶Btk, objectType=article, longId=6326, objectId=9f4b63262b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f4b63262b, replyNumber=0, likeNumber=29, createdTime=2012-05-21, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f4b63262b, moduleTitle=JBC: NK细胞的激活需要络氨酸激酶Btk, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f4b63262b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BTK

2020-05-29

fengting7 (审核中...)

前往app查看评论内容

#BTK#

恒瑞3.5亿美元转让BTK抑制剂，全球很大HIV组织怒斥吉利德“无耻”……

2018-01-17

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK选择性不可逆抑制剂的发现之旅

2017-10-19

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：具有临床活性的BTK抑制剂PCI-32765(伊布替尼)靶向干预慢性淋巴细胞白血病B细胞受体和趋化因子调控的粘附与迁移

2017-10-19

fengting7 (审核中...)

前往app查看评论内容

#BTK#

【CSCO 2017】黄慧强教授专访：浅谈套细胞淋巴瘤的治疗及BTK抑制剂的疗效

2017-10-19

fengting7 (审核中...)

前往app查看评论内容

#BTK#

J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性

2017-10-19

fengting7 (审核中...)

前往app查看评论内容

#BTK#

全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-10-19

fengting7 (审核中...)

前往app查看评论内容

#BTK#

重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-09-01

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Gut：BTK激酶与食管癌

2017-08-26

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Sci Rep：中科院刘青松教授研发出治疗类风湿性关节炎的BTK抑制剂

2017-04-20

fengting7 (审核中...)

前往app查看评论内容

#BTK#

J Immunology：BTK介导Tfh分化促进自身免疫反应的发生

2016-06-02

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：靶向BTK新药ONO/GS-4059对耐药淋巴瘤有良好的安全性和疗效

2015-11-21

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Clin Cancer Res：Ibrutinib治疗能抑制BTK和VLA-4依赖粘附的慢性淋巴细胞白血病

2015-06-25

fengting7 (审核中...)

前往app查看评论内容

#BTK#

PNAS：酶BTK在抗病毒感染中发挥关键作用

2012-08-24

fengting7 (审核中...)

前往app查看评论内容

#BTK#

JBC: NK细胞的激活需要络氨酸激酶Btk

2012-05-21

科室
- - 订阅+
  - 更多科室
工具
服务